Deepinder Goyal's wearable startup Temple launched with novel metrics like BrainFlow, claiming to track blood flow to the brain. Research papers on its website explicitly state it cannot directly measure cerebral blood flow, sparking a heated debate on X. This public spat has exposed a glaring lack of regulatory clarity for health-tracking wearables made in India.
The recent contentious battle on X over Deepinder Goyal’s Temple brought India’s wearable validation gap into sharp focus. Current regulations allow manufacturers to sell physiological trackers without the clinical trials expected of medical devices.
Other Indian wearable startups making physiological claims will now face increased scrutiny regarding their validation processes. Regulators will likely need to initiate discussions on a clear framework for health-tracking devices, perhaps within the next 12-18 months.
🇮🇳 Why This Matters for India
For Bangalore and Pune's health tech founders, this regulatory void means navigating product development and marketing claims without a clear blueprint.
The Take
The larger story here is India's gaping regulatory void for health-tracking wearables. Without a clear validation playbook, product managers are flying blind, and the next Temple controversy is inevitable.
Source:  Inc42 ↗